Navigation Links
Lenalidomide safe as single therapy for elderly CLL patients
Date:12/8/2008

SAN FRANCISCO ― The oral medication lenalidomide is safe and well-tolerated for elderly patients with chronic lymphocytic leukemia, a group without a well-defined frontline therapy for their disease, researchers from The University of Texas M. D. Anderson Cancer Center reported today at the 50th annual meeting of the American Society of Hematology.

"Lenalidomide has a favorable toxicity profile and shows signs of activity against CLL in our phase II clinical trial to date," said study presenter Alessandra Ferrajoli, M.D., associate professor in M. D. Anderson's Department of Leukemia.

Patients start on a 5 mg dose of the drug in pill form and the dose escalates over time in 5 mg increments to a maximum of 25 mg. The median age of participants is 72. Chemo-immunotherapy therapy combinations that are effective in younger patients with CLL tend to be associated with a high rate of complications in patients older than 70, Ferrajoli said.

Of 43 patients enrolled in the study, 35 were evaluable because they had been treated for at least three months. Nineteen of these (54 percent) achieved a partial response, where the disease is diminished, 14 patients (40 percent) had stable disease and continue on therapy, and two had their CLL progress.

Lenalidomide also rapidly reduced the number of circulating lymphocytes the hallmark of the disease in the patients' blood. Ferrajoli said 47 percent achieved a blood complete response and 38 percent had at least a partial response.

Patients on the trial for at least two months were evaluated for the drug's potential side effects. Of those 39 patients, 10 (26 percent) had decreased bone marrow activity resulting in a decrease in the number of either white blood cells called neutrophils or of platelets. Three patients had infections, two had fever and one had pneumonia.

All patients registered in the study remain alive with 37 of the 43 continuing on treatment. Ferrajoli said the trial will include up to 60 patients.

Lenalidomide, a drug developed by Celgene Corp. known commercially as Revlimid, attacks both malignant cells and the cellular environment that nurtures them. The U.S. Food and Drug Administration has approved the drug for treatment of multiple myeloma and some forms of myelodysplastic syndrome.


'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. SurgiQuest Announces First Single Port Procedure for Uterus and Ovary Removal Using AirSeal(TM) Access System
2. Brigham and Womens Hospital Selects SinglePointe(TM) Automated Patient-Specific Medication Management Solution from Omnicell
3. Single in the City? How the Holidays Leave the Fabulous Feeling More Like Failures
4. First and Only Single Capsule Daily Rx Prenatal Vitamin With Plant-Based DHA Now Available
5. Elseviers New Imaging Consult Features In-Depth, Authoritative Information For Diagnostic and Interventional Imaging and Procedures in a Single Online Resource
6. Study Singles Out Beachgoers Skin Cancer Risk
7. Most Single Adults Not Using Condoms
8. University Of Minnesota Gives 11,538 Flu Shots Tuesday, Shattering Guinness World Record for Most Flu Shots in a Single Day
9. New Prostrates Grown From Single Stem Cell
10. HIV Can Re-Emerge From a Single Cell
11. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase Up to $18 Million of Senior Convertible Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... 2016 , ... AHRA: The Association for Medical Imaging Management ... will serve as keynote speaker at the organization’s 2016 Spring Conference. Fox’s topic, ... effectively communicate with their own organizational staff and leadership. , “I am ...
(Date:2/10/2016)... ... February 10, 2016 , ... The Club ... awarded the prestigious Distinguished Emerald Club of the World award, as determined by ... one of the most respected trade publications serving private clubs. , “We’d like ...
(Date:2/10/2016)... Petaluma, CA (PRWEB) , ... February 10, 2016 , ... ... newest and most versatile series of monitor mounts ever. , “Our goal was ... flexible and easy to install system that we have ever created.” said Darren Hulsey, ...
(Date:2/10/2016)... ... ... A new leadership team for Mid-South Youth Camp, operated by Freed-Hardeman University, will ... night, Feb. 8, prior to the evening session of the university’s 80th Annual Bible ... Camp, has been named director. Gayle McDonald, currently the assistant director of MSYC, will ...
(Date:2/10/2016)... ... February 09, 2016 , ... Traumatic Brian Injury ... injury may be one of many possible sources: sports, car accidents, falls, work ... , Mastering Rehab Solutions for the Complexities of Concussions is designed ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... 10, 2016 CERS ), Medivation, Inc. ... ) and Celldex Therapeutics, Inc. (NASDAQ: CLDX ). ... Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS ) and Celldex Therapeutics, ... Orphan Drug Designations become vitally important in the development of ... drugs and biologics which are defined as those intended for ...
(Date:2/10/2016)... /PRNewswire/ - The President of New Venture Medical, ... an anti-radiation product from their Research and Development ... treatment of cancer using radiation and the treating ... the healing of radiation burns, even when open ... the healthy cells from radiation damage. It selectively ...
(Date:2/10/2016)... , Feb. 10, 2016  Silicon Biosystems Menarini ... products that help uncover the biological complexities of ... Inc., a developer of innovative technologies for genomics ... partnership aimed at enabling translational researchers to obtain ... couple hundred tumor and normal cells in an ...
Breaking Medicine Technology: